Literature DB >> 6467208

Immunohistology of normal and ovarian cancer tissue with a monoclonal antibody to placental alkaline phosphatase.

C A Sunderland, J O Davies, G M Stirrat.   

Abstract

A monoclonal antibody, designated NDOG2, has been shown to react with placental alkaline phosphatase. It does not bind to liver, kidney, bone, or intestinal alkaline phosphatase enzymes and has shown a positive reaction with all of over 50 placentae. Immunohistological studies have shown (a) a reaction with respiratory bronchiolar epithelium of lung, endocervical gland epithelium, the epithelium of fallopian tube, and certain reticular cells in the thymic medulla; (b) no detectable staining with ten other normal tissues including testis and tonsil; and (c) a significant reaction with nine of 13 ovarian cystadenocarcinomas and little or no staining with four malignant ovarian tumors of other histopathological types. The NDOG2 antibody may be of value as a marker in patients with ovarian cystadenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467208

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Monoclonal antibodies that recognize different membrane proteins that are deficient in Rhnull human erythrocytes. One group of antibodies reacts with a variety of cells and tissues whereas the other group is erythroid-specific.

Authors:  N Avent; P A Judson; S F Parsons; G Mallinson; D J Anstee; M J Tanner; P R Evans; E Hodges; A G Maciver; C Holmes
Journal:  Biochem J       Date:  1988-04-15       Impact factor: 3.857

2.  Expression of CD1D mRNA transcripts in human choriocarcinoma cell lines and placentally derived trophoblast cells.

Authors:  H J Jenkinson; S D Wainwright; K L Simpson; A C Perry; P Fotiadou; C H Holmes
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

3.  Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease.

Authors:  K L Simpson; A Jones; S Norman; C H Holmes
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

4.  Radionuclide imaging of ovarian tumours with a radiolabelled (123I) monoclonal antibody (NDOG2).

Authors:  P C Jackson; E M Pitcher; J O Davies; E R Davies; C S Sadowski; G E Staddon; G M Stirrat; C A Sunderland
Journal:  Eur J Nucl Med       Date:  1985

5.  Practical applications of a monoclonal antibody (NDOG2) against placental alkaline phosphatase in ovarian cancer.

Authors:  J O Davies; E R Davies; K Howe; P Jackson; E Pitcher; B Randle; C Sadowski; G M Stirrat; C A Sunderland
Journal:  J R Soc Med       Date:  1985-11       Impact factor: 5.344

6.  Tumor markers in the human ovary and its neoplasms. A comparative immunohistochemical study.

Authors:  E J Nouwen; P G Hendrix; S Dauwe; M W Eerdekens; M E De Broe
Journal:  Am J Pathol       Date:  1987-02       Impact factor: 4.307

7.  Distribution of Fc gamma receptors on trophoblast during human placental development: an immunohistochemical and immunoblotting study.

Authors:  S D Wainwright; C H Holmes
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

8.  Placental alkaline phosphatase in benign and malignant endometrium.

Authors:  J O Davies; K Howe; G M Stirrat; C A Sunderland
Journal:  Histochem J       Date:  1985-05

9.  Detection of placental-type alkaline phosphatase in ovarian cancer.

Authors:  I W McDicken; P J McLaughlin; P M Tromans; D M Luesley; P M Johnson
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.